Steven Feldman to Receptors, Tumor Necrosis Factor
This is a "connection" page, showing publications Steven Feldman has written about Receptors, Tumor Necrosis Factor.
Connection Strength
2.177
-
Uhlenhake EE, Feldman SR. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opin Biol Ther. 2010 Jul; 10(7):1105-12.
Score: 0.360
-
Feldman SR. Intermittent dosing of biologics for psoriasis. J Dermatolog Treat. 2006; 17(1):5.
Score: 0.264
-
Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series. J Dermatolog Treat. 2006; 17(2):86-9.
Score: 0.264
-
Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005 Nov; 53(5):887-9.
Score: 0.261
-
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
Score: 0.112
-
Tan X, Balkrishnan R, Feldman SR. Infections associated with the use of tumor necrosis factor-a inhibitors in psoriasis. J Drugs Dermatol. 2013 Mar; 12(3):e41-5.
Score: 0.108
-
Kaminska E, Patel I, Dabade TS, Chang J, Qureshi AA, O'Neill JL, Balkrishnan R, Feldman SR. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. J Dermatolog Treat. 2013 Apr; 24(2):101-6.
Score: 0.097
-
Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr; 22(2):65-74.
Score: 0.089
-
Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219(3):209-18.
Score: 0.085
-
Yentzer BA, Yelverton CB, Simpson GL, Simpson JF, Hwang W, Balkrishnan R, Feldman SR. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009 Apr 15; 15(4):1.
Score: 0.083
-
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
Score: 0.075
-
Sumner W, Feldman SR. Conversion to positive tuberculosis test during etanercept treatment of psoriasis. J Drugs Dermatol. 2007 Oct; 6(10):1048.
Score: 0.074
-
Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol. 2007 Dec; 57(6):972-6.
Score: 0.074
-
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006; 17(2):96-107.
Score: 0.066
-
Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther. 2004; 17(5):376-82.
Score: 0.057
-
Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012 Aug; 11(8):957-62.
Score: 0.026
-
Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011 Jun; 22(3):138-43.
Score: 0.023
-
Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008 Dec; 24(12):3493-501.
Score: 0.020
-
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
Score: 0.019
-
Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
Score: 0.019